Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Recurrence 2Peritoneal Neoplasms 2Lung Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Pneumonitis 1Patients With Any Advanced Solid Tumors 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × nintedanib × Clear all
NCT01004003 2017-10-26

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Boehringer Ingelheim

Phase 2 Completed
125 enrolled 19 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00987935 2016-03-10

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Boehringer Ingelheim

Phase 2 Completed
134 enrolled 29 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01594125 2016-02-12

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡